Zalicus Reports Financial Results for the Fourth Quarter and Year End 2012

  Zalicus Reports Financial Results for the Fourth Quarter and Year End 2012                           Provides Key Goals for 2013  Business Wire  CAMBRIDGE, Mass. -- March 6, 2013  Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2012.  “We are focused on advancing the development of our ion channel programs, including Z160, our first-in-class, oral N-type calcium channel blocker for the treatment of chronic neuropathic pain and Z944, a novel oral T-type calcium channel blocker,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “During 2012 we made a number of advances with our novel ion channel programs, including advancing Z160 into Phase 2a clinical development and Z944 into the clinic. We plan to build on this success in 2013 by generating proof-of-concept data for Z160 in multiple indications and continuing the clinical development of Z944.”  Fourth Quarter 2012 and Recent Accomplishments:    *Z160. Advanced Z160, a first-in-class, oral, state dependent, selective     N-type calcium channel (Cav 2.2) blocker into the second of two Phase 2a     clinical trials for the potential treatment of chronic neuropathic pain,     including lumbosacral radiculopathy which began in the third quarter of     2012 and postherpetic neuralgia which began in the fourth quarter of 2012.     Top line data from both studies are expected to be available late in the     second half of 2013.   *Z944. Received a key U.S. patent issued in February 2013 providing broad     patent coverage for Z944, a novel, oral, T-type calcium channel blocker,     through April 2029. Z944 completed Phase 1 single and multiple ascending     dose clinical studies in late 2012 and the Company plans to continue     further clinical development with Z944 during 2013.   *cHTS™. Generated approximately $7.3 million of revenue in 2012 from our     combination High Throughput Screening (cHTS) collaborations.  2013 Zalicus Pipeline and Business Goals:  Zalicus has set the following goals for 2013, which include internal research and development programs, collaborations and financial goals:    *Ion Channel Programs:         *Successfully advance Z160 through Phase 2a proof-of-concept clinical          studies and report top-line data by year-end 2013        *Advance Z944 through further clinical development including          completing one experimental medicine clinical study in 2013        *Nominate a sodium channel lead for further preclinical development in          2013    *Continue to expand and diversify our cHTS services to generate surplus     cash for the Company   *Target year-end on-going financial strength with sufficient cash through     2014  Fourth Quarter and Year-End 2012 Financial Results (Unaudited):  As of December 31, 2012, Zalicus had cash, cash equivalents, restricted cash and short-term investments of $36.4 million compared to $49.7 million on December 31, 2011.  For the year ended December 31, 2012, revenue was $12.6 million compared to $8.2 million for 2011. Zalicus recognized $5.2 million in royalty revenue from Mallinckrodt based on Exalgo® sales for the year ended December 31, 2012 and a total of $9.4 million in Exalgo royalty revenue from its commercial launch in April 2010 through December31, 2012. The increase in revenue for the year ended December 31, 2012 was primarily due to an increase in Exalgo royalties and collaboration revenue from Novartis. We expect revenue for the year ending December31, 2013 to be higher than that recorded in the year ended December31, 2012 due to higher expected royalties on Mallinckrodt’s net sales of Exalgo and increased cHTS collaboration revenue.  For the year ended December 31, 2012, net loss was $44.3 million, or ($0.38) per share, compared to a net loss of $42.0 million, or ($0.43) per share, in the year ended December 31, 2011. Exalgo amortization expense was $3.9 million for the year ended December 31, 2012 and $5.1 million for the year ended December 31, 2011. Stock-based compensation expense was $1.8 million and $2.2 million in the years ended December 31, 2012, and 2011, respectively. Depreciation expense was $1.5 million and $2.1 million in the years ended December 31, 2012, and 2011, respectively.  Research and development expenses were $41.4 million in the year ended December 31, 2012 compared to $35.3 million in the year ended December 31, 2011. The $6.1 million increase from the 2011 period to the 2012 period was primarily due to an increase in expenses related to the clinical development of Z160 and Z944. We expect research and development expense to decrease for the year ending December31, 2013 due to terminated development activities related to our discontinued product candidate Synavive.  General and administrative expenses were $9.0 million in the year ended December 31, 2012 compared to $10.4 million in the year ended December 31, 2011. We expect our general and administrative expense for the year ending December31, 2013 to be consistent with the year ended December 31, 2012.  About Zalicus  Zalicus Inc. (Nasdaq Global Market: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain such as Z160 and Z944 and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit  Forward-Looking Statements  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its product candidates, their potential, and its plans for clinical development, the Zalicus selective ion channel modulation technology, and related preclinical product candidates, Zalicus’ combination drug discovery technology, cHTS, and its financial condition, results of operations, including expected 2013 royalties on Mallinckrodt’s net sales of Exalgo, and other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus and its product candidates may be identified by words like "believe," "expect," "may," "will," "should," "seek," “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the formulation and clinical development of its product candidates Z160 and Z944, the unproven nature of the Zalicus ion channel drug discovery technology, risks related to the sale and marketing of Exalgo by Mallinckrodt, the ability of Zalicus’s collaboration partners to initiate and successfully complete clinical trials of their partnered product candidates, Zalicus’s ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of Zalicus' annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.  (c) 2013 Zalicus Inc. All rights reserved.  Zalicus Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited)                                                                                          Three months ended                 Twelve months ended                      December 31,                       December 31,                                                                               2012              2011             2012              2011                                                                                                                                                       Revenue: Collaborations       $ 3,674           $ 2,553          $ 12,097          $ 7,595 and other Government contracts and         114             84             453             589         grants                                                                            Total revenue         3,788           2,637          12,550          8,184                                                                                  Operating expenses: Research and           8,930             9,616            41,423            35,294 development General and            1,805             2,370            8,977             10,400 administrative Amortization           972               1,286            3,892             5,141 of intangible Restructuring         (18         )    —              1,094           —                                                                                      Total operating             11,689          13,272         55,386          50,835      expenses                                                                            Loss from              (7,901      )     (10,635    )     (42,836     )     (42,651    ) operations Interest               30                36               150               136 income Interest               (487        )     (397       )     (2,173      )     (976       ) expense Other income          71              18             91              20                                                                                     Net loss before benefit         (8,287      )     (10,978    )     (44,768     )     (43,471    ) for income taxes Benefit for           —               211            441             1,428       income taxes                                                                            Net loss             $ (8,287      )   $ (10,767    )   $ (44,327     )   $ (42,043    )                                                                            Net loss per share—basic          $ (0.06       )   $ (0.11      )   $ (0.38       )   $ (0.43      ) and diluted                                                                            Weighted average number of common shares used in net loss              126,989,856     99,231,443     117,316,968     97,347,193  per share calculation —basic and diluted                                                                            Net loss             $ (8,287      )   $ (10,767    )   $ (44,327     )   $ (42,043    )                                                                            Other comprehensive loss: Unrealized gain on               —               22             18              12          investments                                                                            Comprehensive        $ (8,287      )   $ (10,745    )   $ (44,309     )   $ (42,031    ) loss                                                                                                                                                                                  Zalicus Inc. Consolidated Balance Sheets (in thousands, except per share data) (Unaudited)                                                                                                                  December 31,                                                    2012           2011 Assets Current assets: Cash and cash equivalents                          $ 4,531        $ 2,750 Restricted cash                                      50             50 Short-term investments                               30,059         45,124 Accounts receivable                                  3,045          1,886 Prepaid expenses and other current assets           684          1,397                                                                        Total current assets                                 38,369         51,207 Property and equipment, net                          3,535          5,258 Intangible asset, net                                17,654         21,546 Restricted cash and other assets                    1,817        1,872                                                                        Total assets                                       $ 61,375      $ 79,883                                                                       Liabilities and stockholders’ equity Current liabilities: Accounts payable                                   $ 3,261        $ 1,743 Accrued expenses and other current                   4,841          6,133 liabilities Deferred revenue                                     4,918          3,349 Current portion of term loan payable                 6,327          4,035 Current portion of lease incentive                  284          284       obligation                                                                    Total current liabilities                            19,631         15,544 Term loan payable, net of current portion            8,772          15,099 Deferred revenue, net of current portion             600            3,000 Deferred rent, net of current portion                457            605 Lease incentive obligation, net of current           875            1,159 portion Other long-term liabilities                          14             563 Stockholders’ equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and              —              — outstanding Common stock, $0.001 par value; 200,000 shares authorized; 127,019 and 99,239 shares issued                                               127            99 and outstanding at December 31, 2012 and 2011, respectively Additional paid-in capital                           371,912        340,518 Accumulated other comprehensive income               10             (8       ) (loss) Accumulated deficit                                 (341,023 )    (296,696 )                                                                    Stockholders’ equity                                31,026       43,913                                                                       Total liabilities and stockholders’ equity         $ 61,375      $ 79,883                                                                                   Contact:  Zalicus Inc. Justin Renz, 617-301-7575 CFO or Gina Nugent, 617-460-3579  
Press spacebar to pause and continue. Press esc to stop.